Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study

The Lancet Oncology 2026 Open access

Read full text
Authors: Andrea Necchi, Brigida A Maiorano, Joep J de Jong, James A Proudfoot, Giuseppe Basile, Antonio Cigliola, Chiara Mercinelli, Valentina Tateo, Michela Piacentini, Giovanni Luigi Pastorino, Gaia Latini, Enrico Tomasi
+9 more Elai Davicioni, Marco Moschini, Giorgio Brembilla, Maurizio Colecchia, Francesco de Cobelli, Alberto Briganti, Jeffrey S Ross, Dean C Pavlick, Francesco Montorsi
DOI: 10.1016/s1470-2045(26)00050-1
Cited by: 14
References: 25

Fields of Study & Subjects

Bladder and Urothelial Cancer Treatments Cancer Immunotherapy and Biomarkers Renal cell carcinoma treatment

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
4
Pages
442–451
Publication date
27 February 2026
Language
EN